Thursday, December 15, 2022

Guest Blog Contributor - A Year of Enlightenment

By: Ranier Simons, ADAP Blog Guest Contributor

This is my last blog post of 2022. It is hard to believe that a year has already passed. It does not feel like I have been a guest blog contributor for an entire year. When I was blessed with the opportunity to contribute, I was unsure of what to expect. As every writer knows, the end product is always the result of creating something from nothing. In the case of this blog, the ‘something’ is not some fanciful creative writing artistic endeavor. The ‘something’ is meant to educate, reveal, inspire action, promote, support, highlight, battle misinformation and in some cases disinformation. Writing for this blog is acceptance of the responsibility to make sure every blog is properly researched, has a purposeful message, and most importantly respects and does not waste the time of those who take the time to read it. 

Desk with laptop, pen and pad, iPhone, and cup of coffee
Photo Source: JerryJenkins.com

I have a master’s degree in healthcare innovation, many years of science and medical education and research experience, firsthand experience as a healthcare worker, life experience as a caregiver, and I am currently a clinical operations healthcare data analyst. However, those things are not why I felt equipped to write for this blog. I felt confident to effectively contribute because I knew I was willing to dig into the jargon-filled weeds of medical journals and other scientific periodicals, scour digital sites of evidence-based discourse, and seek insight from experts in order to distill information into a format easily accessible to all. Communication goes both ways. Real communication happens when information is delivered and the recipients truly comprehend and digest what is given. Medical discourse regarding HIV/AIDS and other related healthcare issues is vast. This makes distillation very important.

My path has crossed with many people living with HIV/AIDS, some of whom have passed due to HIV/AIDS. I have been very close to a good number of them and tangentially exposed to others. Even though I have a high level of exposure to the HIV/AIDS landscape, I was not fully aware of all of the layers before this year of contributing to his blog. I learned about a few HIV/AIDS concepts and related disease etiologies of which I was not previously aware. Researching some of the posts resulted in my discovery of resources I didn’t know about. Most importantly, writing for this blog revealed to me the vastness of the global network of people working towards the eradication of HIV/AIDS on many different levels.

TOGETHER
Photo Source: African Constituency

The most important thing I’ve gleaned as a guest blog contributor is how far we have left to go in the fight against HIV/AIDS. Because medical science has advanced to the point of treating it like a chronic disease, on the surface it seems as if the general public doesn’t view it with the same sense of urgency or danger as in the past. However, there is so much more work to be done, so many more people to reach, so many more policies to write and change, so much more research to be done, many more breakthroughs to discover, and multitudes of lives to save.

Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates. 

Thursday, December 8, 2022

Why a Secure Drug Supply Chain Matters

By: Brandon M. Macsata, CEO, ADAP Advocacy Association
       Shabbir Imber Safdar, Executive Director, Partnership for Safe Medicines

Since the start of the AIDS crisis, people living HIV (PLWHA) have looked forward to a day when medicines could allow them to live a life in which their HIV is undetectable and untransmittable (otherwise known as, “UequalsU). Today, PLWHA with access to treatment and adherent to their antiretroviral therapy are expected to live well into their 80’s. There is so much promise in the fight to end the epidemic. 

PLWHA can be confident of the security of those medications from fraudsters because they are protected by the Drug Supply Chain Security Act (DSCSA). This medication protection system, originally created in 2013, completes its rollout next year in 2023. It assigns a number to each package of medicine at time of manufacture, and that number is tracked at every change of ownership from factory to distributor to pharmacist. “Track and trace” is the name associated with this drug supply safety system.

Pharmacist scanning Rx medicines
Photo Source: Pharmaceutical Technology

Though criminals never stop trying to defraud patients and pharmacists, we know the DSCSA works because it has been tested. A pharmacist in Texas who checked the serial numbers on “too-cheap-to-be-true” HIV medicine discovered fraud and returned that medicine to the seller without dispensing it to patients. Furthermore, because these kinds of serial numbers allow very fine-grained tracking of medicine in the supply chain, no broad recalls were necessary which might have taken perfectly good medicine off the market and endangered patient access.

DSCSA has protected PLWHA and all patients in the United States, but as with any system, it needs support. There are two key places where the federal government needs to help:

  • Charge people who forge DSCSA paperwork with DSCSA fraud
Criminals, such as the recent spate of HIV counterfeit criminals, have yet to be charged with criminal offenses for DSCSA fraud. In fact, to-date there is no record of anyone ever having been charged with DSCSA fraud. To protect patients there must be a deterrent to forging DSCSA paperwork, and to do that, the DOJ must ensure that this crime draws a criminal charge.

There are currently 140 defendants in the existing civil litigation brought by Gilead Sciences and Johnson and Johnson Healthcare Systems against the criminals trafficking in counterfeit and diverted HIV and Hepatitis C (HCV) medications. Not even one has drawn a criminal charge of forging DSCSA paperwork. 

The Biden Administration’s Department of Justice needs to make prosecution of criminals who violate the DSCSA a priority with resources and training.

  • Do not undermine the DSCSA for political expediency
For decades it has been in vogue to suggest buying medicine from other countries to make it cheaper. However, countries suggested, like Canada, don’t have a system like DSCSA and we cannot provide this same level of safety assurance to patients and pharmacists. Regulations that intentionally break the DSCSA, like the regulations that govern bulk importation of drugs from Canada that break the DSCSA will endanger HIV, HCV, and many other categories of American patients.

The Administration’s Department of Health & Human Services needs to revoke the rules governing bulk importation until Canada has an interoperable DSCSA system to protect medicine imported.

Ensure broad understanding of DSCSA features for physicians

As the DSCSA finishes its rollout, one part of the dispenser community unlikely to get the message is physicians who administer long-acting HIV injectables. These injectables, which can control HIV with just two shots every month or two months, are an enormous innovation.

However recent history includes a few failures of physicians to understand the dangers of criminals in the supply chain, including:

Unlike pills taken by PLWHA, which can be examined by the pharmacist and patient, injectables administered by physicians don’t necessarily have this protection. Additional steps are needed to ensure patients can participate in medication verification safety. All too often, patients never see touch the injectable, and likely never see the packaging it came in. Physicians, who are not typically trained to check pharmaceutical wholesaler licenses or verify DSCSA safety features, have repeatedly been the targets for criminals. PLWHA need to be empowered to involve themselves more in this process.

How to Spot Fake HIV Medicines
Download Infographic

As the DSCSA rollout proceeds, we urge the Biden Administration to resource the U.S. Food & Drug Administration (FDA) so they can prioritize education of physicians about the new security features of the DSCSA and the risks to their patients and their practice if they ignore them.

People living with HIV in the United States have witnessed significant progress in managing their condition. The advent of new medicines has greatly improved their quality of life greatly, and equally the safety of their drug supply has been enhanced by the Drug Supply Chain Security Act. It’s critical that we do everything possible to support it.

Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates.  

Thursday, December 1, 2022

Advocacy Needed to Reduce Barriers to Accessing Long-Acting Agent Therapies

By: Ranier Simons, ADAP Blog Guest Contributor

Medical science continues to advance at a rate that outpaces healthcare policy and subsequently healthcare practices. This is especially true regarding novel lifesaving therapies and modalities for chronic diseases such as HIV/AIDS. Treatment for people living with HIV/AIDS (PLWHA) is expensive, long-term, and requires consistency in its administration to be effective. Moreover, antiretroviral medications and other related compounds are rapidly evolving. There have already been challenges to ensure equal access, for all, for established and widely used therapies. The situation is even more dire for some of the newest treatments available. That is why the ADAP Advocacy Association created its ADAP Injectables Advisory Committee

ADAP Update
Photo Source: PRC

The advisory committee was a collaboration of patients, as well as representatives from pharmaceutical manufacturers, advocacy groups, healthcare providers, and pharmacy groups. In August 2022, the advisory committee released its report: HIV LONG-ACTING AGENTS: Policy Considerations for Injectable Therapies under the Ryan White HIV/AIDS Program & State AIDS Drug Assistance Programs. It was in response to the need to reduce the operational burdens and other barriers of ensuring that PLWHA dependent upon the State AIDS Drug Assistance Program (ADAP) for their care receive equal access to newly developed injectable treatments in the same manner as people who are fully insured. The report also addressed barriers experienced under private insurance.

Long-acting agents include more than just antiretroviral therapies, such as Cabenuva, which is used to treat HIV. They also include treatments such as Apretude, an injectable used as PrEP, Egrifta used to reduce visceral abdominal fat as a result of lipodystrophy, Serostim for wasting, and Trogarzo which is intravenous therapy for those with multi-drug resistant HIV infections. 

These therapies are proven to be effective. However, not only are they expensive, but they are logistically challenging for supply and administration even for those who are fully insured. The challenge is even greater for those who utilize ADAP. The report described policy considerations to improve equity of care regarding injectables. Those considerations included discussions of how to reduce provider bias in offering injectable therapy as an option, ways to expand the network of facilities where injections and intravenous therapies can be administered for ADAP recipients, and ways to utilize community level resources for peer education and advocacy. 

Long-acting antiretrovirals
Photo Source: Regional Center for Infectious Disease Research

A very important section of the report involved insurance. ADAP’s have formularies just in the same manner as insurance plans. Moreover, ADAP can use private insurance for patients for medication and can now assist with paying insurance premiums for low-income patients. The report discussed ways to navigate ADAP versus Medicaid insurance coverage for injectables. There was also policy discussion of how to maintain drug formularies to ensure consistent coverage.

HIV long acting agents are powerful tools in the fight against HIV and those utilizing ADAP deserve the same equity of care and access as those who are fully insured with more robust financial means. Whether it be geographical logistical challenges, treatment education deficiencies, supply chain issues, or even provider bias; ADAP recipients have many injection therapy barriers to overcome. The work of the ADAP Injectables Advisory Committee was to define necessary policy changes as well as guide discussions on how organizations can provide more ADAP recipient patient-centered care. Click here to read the report's cover letter, executive summary, and full report.

Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates. 

Tuesday, November 22, 2022

Giving Thanks

By: Brandon M. Macsata, CEO, ADAP Advocacy Association

In 2021, we started a new tradition by "giving thanks" to the things important to our organization, as well as me, personally. All too often we get caught up in the nuances of our advocacy work, and monitoring the dysfunctional legislative logjam that has become commonplace in our nation's capital (especially, keeping an eye out for dangerous legislation, such as S.4395), as well as chasing potential funders so we can keep the proverbial lights on. This tradition was started, in large part, because we lost our Lion of the modern-day HIV/AIDS advocacy movement: Bill Arnold

Eddie Hamilton (l) with Bill Arnold (r)
Eddie Hamilton (l) with Bill Arnold (r)

Sadly, we lost another giant personality in our ongoing fight to end the HIV epidemic. On July 12th, Edward "Eddie" Hamilton passed from this life into the next, but not without leaving his mark on many of our lives. Eddie was special because held state and local health departments to account; he held commercial healthcare providers and retail pharmacies to account; he held community-based organizations to account; he held advocacy coalitions to account; and he also held all of us to account, always reminding anyone who could hear his voice why we are here doing this work…for the patient. But I'm giving thanks for having known such a wonderful, unique, and complicated human being.

Next, I'm giving thanks to the VOTERS (...well, a majority of them) because they rejected the politics of anger, division, hate, and violence! Our Democracy is too sacred, too important. Two years ago, we witness a former president desperately clinging to power incite a seditious mob to attack the very symbol of our government. The law enforcement sworn to protect our government officials were beaten; people died. Yet, we didn't forget about it and on November 8th, America said...enough!!!

That statement was pretty intense, but it needed to be made.

I'm also giving thanks to Phil, Wanda, Jen, Eric, Lyne, Hilary, Lisa, Glen, Jennifer, Theresa, and Guy. As my board of directors, they embody a commitment to excellence. Some of these folks have served in their leadership role for many years; others, only a few. Collectively they have contributed so much of their experience, knowledge and passion into making the ADAP Advocacy Association more effective as a patient advocacy organization. I'm also giving thanks to our longtime board member, Elmer Cerano, who recently stepped-down from our board of directors after serving for fourteen years! He was our compass, always ensuring that we never veered from the path our mission.

HIV Long-Acting Agents

This year, we embarked on an ambitious project to advance better patient advocacy surrounding access to HIV Long-Acting Agents (LAAs). Our ADAP Injectables Advisory Committee included Michelle Anderson with the Afiya Center, Tori Cooper with the Human Rights Campaign Foundation, Donna Sabatino with The AIDS Institute, Jennifer Eliasi MS, RD, CDN with Theratechnologies, Marcus Hopkins with Appalachian Learning Initiative, Jen Laws with the Community Access National Network (CANN), Warren Alexander O'Meara-Dates with The 6:52 Project Foundation, Dawn Patillo-Exum with Merck, Glen Pietrandoni, R.Ph with Avita Pharmacy, Cindy Snyder with  ViiV Healthcare, Alex Vance with the International Association of Providers of AIDS Care (IAPAC), Marcus Wilson with Janssen Pharmaceutical Companies of Johnson & Johnson, and Joey Wynn with the Florida HIV/AIDS Advocacy Network (FHAAN). I'm giving thanks to each and every one of you for the amazing work you completed on our behalf!

In last year's thankful reflection, I said: "The dogmatic claims that industry funding is paramount to a bride are not only unfounded, they're also unhelpful to our collective efforts to improve access to care and treatment." It still holds quite true, and thus why I'm giving thanks to our industry, and non-industry funders, including AbbVie, AIDS Alabama, Avita Pharmacy, Bender Consulting Services, Brii Biosciences, Bristol-Myers Squibb, Community Access National Network, Gilead Sciences, Janssen Pharmaceutical Companies of Johnson & Johnson, Magellan Rx Management, Maxor National Pharmacy Services Company, MedData Services, Merck, Napo Pharmaceuticals, North Carolina AIDS Action Network, Novartis, Partnership for Safe Medicines, Patient Access Network Foundation, Patient Advocate Foundation, PayPal Giving Fund, Pharmaceutical Research and Manufacturers of America, Ramsell Corporation, ScriptGuideRx, Theratechnologies, ViiV Healthcare, and Walgreens. Giving thanks to our small donors, too. You could donate to so many other charities, yet you choose to support us!

Pa Pa holding Sebastian
Sebastian Ryan Macsata

And once again, I'm giving thanks to my four-year son, Sebastian. Being your Pa Pa is the most joyous part of my life and I couldn't imagine a day without your smile starting off my day. I'm thankful for being able to witness your innocence, because it reminds me that there is still good in this crazy world.

Finally, giving thanks to YOU for reading our blogs every week. Happy Thanksgiving!

Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates.  

Thursday, November 17, 2022

Gay and Bisexual Youth Account for Almost 80% of all New HIV Infections Among Their Age Cohort

By: Ranier Simons, ADAP Blog Guest Contributor

The HIV epidemic is far from over. In spite of advances in antiretroviral drug treatment regimens, public-private funding partnerships, and continued outreach and education efforts; the number of new HIV infections each year remains unacceptable. In 2020, 30,635 people aged 13 and older received an HIV diagnosis in the United States.[1] The age group 13-24 accounted for 57% of new diagnoses.[1] Moreover, among teens, gay and bisexual youth account for almost 80% of all new HIV infections.[2] Public health initiatives and advertising have targeted adults but have been lacking in regard to teens and youth.

Three gay, young men sitting on the floor
Photo Source: HIV Plus Magazine

A recent three-month study, published in the journal AIDS and Behavior, attempts to explore ways to effectively reach part of this group, specifically gay and bisexual young men. The premise is that parents can be used as an effective resource to prevent HIV in this demographic. David Huebner, Professor of Prevention and Community Health at the Milken Institute School of Public Health, George Washington University with a team gathered 61 parents of cisgender sons aged 14-22 who had come out as gay or bisexual at least one month before the study. Set up as a randomized trial, the study split the parents into two groups. In the control group, parents watched a 35-minute documentary that was designed to help parents understand and accept their gay children.  The other group was enrolled in an online program called PATHS (Parents and Adolescents Talking about Healthy Sexuality).[2] The program consisted of videos and structured instruction to help parents more effectively communicate with their gay or bisexual sons about staying healthy and how encourage sexual health. 

Infographic on "What Young Men Who Have Sex  With Men Need"
Photo Source: National Minority AIDS Council

The instruction took into consideration that the parents were not a monolith and had differing levels of comfort in communicating with their children. Thus, the tasks the parents were given allowed some parents to be more indirect and others to be more direct. For example, for educating their sons about condom usage, parents could either text their sons an instructional video or they could physically demonstrate how to properly apply a condom using a banana. In regards to HIV, parents had the option of sending their sons a fact sheet about the risks of HIV or actually sitting down with them and reviewing it together. Most importantly, parents were educated on how to help their sons get HIV tests and why regular testing is important.

The study showed that parents who were engaged in the online program had more quality interactions talking with their sons about sexual health and helped their sons obtain HIV tests than the parents who were simply shown the documentary on acceptance. The research team wants to show that direct intervention with parents will result in better sexual health outcomes for the gay and bisexual sons. With funding from the National Institute of Mental Health, a larger study will be done. This study will be a year-long study of 350 parent-adolescent dyads to see if structured parental instruction actually reduces HIV risk for gay and bisexual adolescent men.

National Youth HIV/AIDS Awareness Day
Photo Source: HIV.gov

April 10 is National Youth HIV/AIDS Awareness Day (NYHAAD). It is designed to raise awareness about the impact of HIV on young people. HIV.gov offers numerous resources and tools to leverage digital communication tools and social media to reach out to youth with prevention, testing, and care messages.

Parents are a previously untapped resource to utilize in HIV prevention efforts among young gay and bisexual males. It is important to not only facilitate changing parents attitudes and understanding of their gay and bisexual sons, but to teach them the actual tools necessary to effectively intervene in the youth’s lives. Multilevel life skills intervention in the home will hopefully lead to better sexual health choices and outcomes as the youth navigate the world around them.

[1] HIV.gov.(2022, October 27). U.S. Statistics. Retrieved from https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics
[2] Henderson, E. (2022, November 2022). Parents represent a promising resource in preventing HIV among gay and bisexual male youth. Retrieved from https://www.news-medical.net/news/20221110/Parents-represent-a-promising-resource-in-preventing-HIV-among-gay-and-bisexual-male-youth.aspx
[3] 
Huebner, D.M., Barnett, A.P., Baucom, B.R.W. et al. Effects of a Parent-Focused HIV Prevention Intervention for Young Men Who have Sex with Men: A Pilot Randomized Clinical Trial. AIDS Behav (2022). https://doi.org/10.1007/s10461-022-03885-1

Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates. 

Thursday, November 10, 2022

Non-AIDS-defining Cancers Among People Living with HIV/AIDS

By: Ranier Simons, ADAP Blog Guest Contributor

The advent of combination antiretroviral therapy (ART) has greatly improved the lives of people living with HIV/AIDS (PLWHA). ART has reduced HIV infection related morbidity and mortality overall and reduced the rates of AIDS defining cancers.[1] AIDS defining cancers are those that PLWHA are at a high risk for developing. When they develop these cancers, it usually means they have advanced from HIV to AIDS. Kaposi sarcoma, certain types of non-Hodgkin lymphoma, and cervical cancer are examples of AIDS-defining cancers.[2] In contrast to ART’s reduction of AIDS-defining cancers, while the risk is decreasing, the incidence of non-AIDS-defining cancers remains.[2] Non-AIDS-defining cancers are those that are more likely to appear in HIV-positive people. Lung cancer is the non-AIDS-defining cancer that appears the most. A recent study indicates that PLWHA remains at a higher risk and incidence of lung cancer compared to the population at large.[3]

Cancer
Photo Source: pratidintime.com

The study does not fully explain the causality of the higher incidence, however it does shed more light onto what is occurring. The U.S. National Cancer Institute performed a population-based registry linkage study using 2001–2016 data from the HIV/AIDS Cancer Match study, which links data from HIV and cancer registries from 13 regions in the USA.[4] There were 4,310,304 subjects followed in the study. During the study span 3,426 developed lung cancer. Compared to the general population, the data showed that PLWHA in their 40’s have twice the risk of developing lung cancer, PLWHA in their 50’s were 61% more likely, and PLWHA in their 60’s were 30% more likely to develop lung cancer.[3] It also noted that lung cancer surpasses Kaposi’s Sarcoma and Hodgkin’s Lymphoma as the leading cancer in PLWHA over the age of 50. That is a notable distinction given that Kaposi’s Sarcoma and Hodgkin’s Lymphoma are AIDS-defining cancers.

One factor contributing to the increased lung cancer incidence is smoking. Tobacco smoking rates are much higher among PLWHA than the general population.[5] There is evidence-based consensus that the lungs of PLWHA are especially susceptible to the harmful effects of cigarette smoke.[6] Additionally, due to HIV infection, their bodies are already in a constant state of inflammation. Cigarette smoking does not completely explain the higher lung cancer risk. Immunosuppression is also a factor. Although ART is very effective, there is still some immunosuppression due to HIV infection. By 2013-2016, half the study population had been living with HIV for at least ten years.[7] Researchers also found that the prognosis was worse and risk high for PLWHA who at any point previously had an AIDS diagnosis.[3] 

Don't Burn Through Your Meds
Photo Source: DCTCF

Medical research is continuing to investigate the etiology of lung cancer in PLWHA. Meanwhile, prevention is paramount. Most early lung cancer is asymptomatic. Thus, discovering cases early through screening before symptoms are seen will result in better outcomes. For some types of lung cancer, the survival rate is around 90% when tumors are discovered while small.[3] In the U.S., screening of adults with a smoking history, aged 50-80, is already recommended. The growing consensus is that screening of PLWHA needs to start earlier. Moreover, HIV status should be considered for inclusion in the entry criteria for lung cancer screening programs.[8]

[1] Moltó, J., Moran, T., Sirera, G., & Clotet, B. (2015). Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. Translational Lung Cancer Research, 4(6), 678-688. doi:10.3978/j.issn.2218-6751.2015.08.10
[2] Cedars Sinai. (2022). AIDS-Related Cancers. Retrieved from https://www.cedars-sinai.org/health-library/diseases-and-conditions/a/aids-related-cancers.html
[3] 
Hudson, D. (2022, October 16). People with HIV are at twice the risk of lung cancer, study finds. Retrieved from https://www.queerty.com/people-hiv-twice-risk-lung-cancer-study-finds-20221016#.Y2J6PmVsaPA.twitter
[4] 
Engels, A. et al. (2022). Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study. Lancent HIV, 9(10), 700-708. https://doi.org/10.1016/S2352-3018(22)00219-3
[5] Centers for Disease Control. (2022). People Living with HIV. Retrieved from https://www.cdc.gov/tobacco/campaign/tips/groups/hiv.html
[6] Rahmanian, S. et al. (2011). Cigarette smoking in the HIV-infected population. Proceedings of the American Thoracic Society, 8(3), 313-319. https://doi.org/10.1513/pats.201009-058WR
[7] Alcorn, K. (2022, October 11). Risk of lung cancer is higher for people with HIV. Retrieved from https://www.aidsmap.com/news/oct-2022/risk-lung-cancer-higher-people-hiv
[8] Hein, I. (2022, October 6). Lung cancer declining in people with HIV, but still high. Retrieved from https://www.medpagetoday.com/hivaids/hivaids/101100

Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates. 

Thursday, November 3, 2022

Start Antiretroviral Therapy Sooner Than Later

By: Ranier Simons, ADAP Blog Guest Contributor

As medical science strives towards eradicating HIV, research and discourse regarding treatment and prevention continue to evolve. Antiretroviral therapy (ART) is the primary method of treatment. ART is drug therapy consisting of various combinations of medications whose purpose is reducing the HIV viral load in the body. The ultimate goal is to reduce the viral levels in the body to the point of being undetectable. Undetectable means that the viral load is so low that a viral load test cannot detect it.[1] Reaching undetectable status means that a person has no risk of sexually transmitting HIV to others, commonly referred to as "U=U" (undetectable equals untransmittable). Research has also shown that maintaining undetectable status enables people living with HIV/AIDS (PLWHA) to live long, healthy lives. 

Antiretroviral therapy for HIV
Photo Source: Very Well Health

The timeline of starting patients on treatment is an ongoing inquiry at the forefront of ART discourse. In addition to viral load, historically, many other factors have been considered when starting PLWHA on drug therapy. Those who are asymptomatic and seemingly very healthy with good CD4 counts sometimes don’t see the benefits of starting early treatment out of concerns about possible long-term side effects and emotionally handling the prospect of lifetime medication adherence.[2] Notwithstanding various psychosocial, financial, and logistical issues, the main clinical criteria inquiry is the CD4 count. 

CD4 cells are white blood cells in the body that help the immune system to fight infection. HIV attacks and destroys CD4 cells.[3] An insufficient number of CD4 cells leaves the body susceptible to many forms of illness that healthy HIV-negative people are protected against. PLWHA are diagnosed with AIDS when the CD4 count reaches 200 cells/mm3.AIDS diagnosis means a high risk of developing life-threatening illnesses or even cancers.

Over time consensus has evolved regarding the appropriate CD4 count threshold for beginning ART. For a long time, the established guidelines recommended ART to begin when CD4 counts dropped below 350 cells/mm3 or if a patient had symptoms of AIDS. In December 2009, U.S. guidelines were issued, including a recommendation that ART commences if the CD4 count is between 350 and 500 cells/mm3.[4] However, that recommendation was based on observational studies, not randomized trials, in the manner that previous guidelines were developed. A randomized trial results in more definitive information since randomization means groups tested are very similar except for received treatment.[4]

To obtain randomized trial results concerning early ART intervention, the Strategic Timing of Antiretroviral Therapy (START) trial was first initiated in 2009, enrolling 4,684 HIV-positive patients (median age 36, 27% women), who had a CD4 count of ≥500 cells/mm3 (median 651 cells/mm3 ) at least two weeks apart within the 60 days before enrollment. Of these patients, 2,325 were randomized to start ART immediately, and 2,359 were randomized to defer treatment until their CD4 count was ≤350 cells/mm3.[5] Subjects were followed for a minimum of three years. START is a multinational endeavor.

Image of medications and a syringe
Photo Source: everydayhealth.com

In 2015, results were published in the New England Journal of Medicine. Data showed that early initiation of ART lowered the risk of severe AIDS-related outcomes, serious non-AIDS-related outcomes, and death by 57%.[4] When the results were published, the subjects who had previously been in the deferred ART group started drug therapy. Another analysis was done in October 2022, which included 4,436 patients who were followed from January 2016 through December 2021. This analysis supported the benefits of starting ART early, even for patients with CD4 counts over 500 cells/mm3 at diagnosis. An additional finding was that adverse outcomes of delayed treatment were more pronounced in patients aged 35 and younger.[4] Research is continuing to examine the outcome difference by age.

Given that the START study shows the importance of early initiation of ART, it is imperative to increase efforts to identify HIV-positive patients. Many people don’t find out until clinically, a lot of damage has occurred. By increasing testing efforts, especially for those in higher-risk groups, HIV infection can be caught at earlier stages, and patients can initiate therapy. Early therapy means a much lower risk of AIDS progression, fewer instances of non-AIDS-related serious issues, and shorter time spans to reaching undetectable status. Diagnosing people earlier means a better quality of life for those infected and an expedited reduction in the number of people with viral loads high enough to be a transmission risk.

[1] National Institute of Health. (2021, August 16). HIV Treatment. Retrieved from https://hivinfo.nih.gov/understanding-hiv/fact-sheets/when-start-hiv-medicines#:~:text=When%20is%20it%20time%20to,possible%20after%20HIV%20is%20diagnosed
[2] Ross, J. et al. (2021) How early is too early? Challenges in ART initiation and engaging in HIV care under Treat All in Rwanda-A qualitative study. PloS one, 16(5), e0251645. https://doi.org/10.1371/journal.pone.0251645
[3] 
National Institute of Health. (2022, August 22). CD4 Lymphocyte Count. Retrieved from https://medlineplus.gov/lab-tests/cd4-lymphocyte-count/
[4] 
Hein, I. (2022, October 25). Start HIV Antiretroviral Therapy ASAP, Experts Urge. Retrieved from https://www.medpagetoday.com/meetingcoverage/idweek/101419
[5] National Institute of Health. (October 4, 2022). Strategic Timing of Antiretroviral Treatment (START). Retrieved from https://clinicaltrials.gov/ct2/show/study/NCT00867048

Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates. 

Thursday, October 27, 2022

HRSA Releases Annual Ryan White Client-Level Report, 2020 - Program Enrollment Varies

By: Marcus J. Hopkins, Founder & Executive Director, Appalachian Learning Initiative

The Health Resources and Services Administration (HRSA) has released the AIDS Drug Assistance Program (ADAP) Annual Client-Level Data Report, 2020. These data reflect the demographic characteristics of clients served by the ADAP program from 2016-2020. This is the second Annual Client-Level Report released in 2020, with the first covering years 2016-2019, and is the first report to include client-level information from the first year of the COVID-19 global pandemic.

Increasing ADAP Enrollment

In 2020, 300,785 clients were served by state ADAP programs across the United States—an increase of more than 3,500 clients from 2019. While this represents a 1.3% increase in national enrollment numbers from 2019 to 2020, 7 states and 2 territories (Guam & U.S. Virginia Islands) saw enrollment increases or decreases of greater than 10% (Figure 1). 

Client enrollment regularly decreases and increases based on a number of factors, including but not limited to:

  • Clients becoming newly eligible or ineligible based upon their income
  • Clients moving from state ADAP programs to state Medicaid programs
  • An increase in new HIV diagnoses and, with the delivery of competent case management services, being enrolled in the program
  • Clients moving into or out of states
  • Clients passing away

2020, however, was unique due to the impacts of the onset of the COVID-19 global pandemic. The original expectation was that increases in unemployment would drive large increases in ADAP enrollment across the U.S. While national enrollment did increase by 1.6%, 31 jurisdictions actually saw decreases in ADAP enrollment from 2019 to 2020 (Table 1).

Because no one state’s ADAP program is identical to another, the reasons for enrollment increases and decreases are highly specific to each state. That said, significant increases and decreases should be carefully examined to identify service disparities, particularly in states where patients face numerous barriers to accessing care and treatment.

Figure 1. Change in State AIDS Drug Assistance Programs (ADAPs) Enrollment, 2019 to 2020

Map showing change in State AIDS Drug Assistance Programs (ADAPs) enrollment 2020
Photo Source: HRSA, 2022

The Demographics of ADAP

78.1% of ADAP clients are cisgender male (i.e., non-transgender male; hereafter referred to as “male”)—a figure that has remained largely unchanged since 2015, and 20.4% were cisgender female (i.e., non-transgender female; hereafter referred to as “female”). 1.6% of ADAP clients identified as transgender (1.3% as transgender female, 0.1% as transgender male, and 0.1% as another gender identity; the total does not equal 1.6% due to rounding). 

Similarly, the racial and ethnic demographics of ADAP clients have remained largely unchanged since 2015, with 39.5% of enrollees being Black Americans, 27.6% being Hispanic/Latino, 29.6% being White, and less than 2% each are Asian, American Indian/Alaska Native, Native Hawaiian/Pacific Islander, and people of multiple races. Of the women who are clients of ADAP, over half (56.5%) are Black. ADAP clients from non-White demographics are consistently younger than White enrollees. 60.5% of White enrollees are aged 50+ years, compared with just 48% of clients who are American Indian/Alaska Native, 40.3% of Native Hawaiians/Pacific Islanders, 39.6% of Black Americans, 38.8% of multiracial clients, 37.8% of Hispanic/Latino clients, and 34.4% of Asian clients.

Additionally, ADAP enrollees have continued to overwhelmingly be at the lowest end of the income eligibility scale, with 49.1% of clients earning between 0% - 100% of the Federal Poverty Level (FPL)—$12,760/year for an individual in 2020.

These demographics have all remained largely unchanged over the past decade in no small part because they are reflective of the HIV epidemic, in and of itself. New HIV diagnoses continue to be disproportionately identified in Black, Brown, and lower-income communities. As a result, those clients compose the majority of ADAP clients.

Health Coverage of ADAP Clients

In 2020, 37.4% of all ADAP clients had no healthcare coverage, whatsoever, including private and employer-sponsored insurance, Medicaid coverage, Medicare coverage, Veterans Administration coverage, Indian Health Services coverage, and other types of coverage. This varies by race, with just 20.7% of White clients lacking healthcare coverage compared with 48.2% of Hispanic clients and 42.8% of Black clients. It also varies by gender, with 37.8% of male clients lacking coverage and 36.2% for females. Trans folx and gender non-conforming individuals were disproportionately impacted by a lack of healthcare coverage, with 34.9% of transgender male clients, 52.6% of transgender female clients, and 59.5% of clients with different gender identities lacking coverage.

With the exception of persons who identify as transgender females, every gender demographic saw at least a 1% increase in the number of clients with private individual insurance from 2019 to 2020. Transgender men saw the largest increased in the number of privately insured clients from 2019 to 2020, with just 16.4% of transgender men being privately insured in 2019 and 26.2% being insured in 2020.

Services Utilization of ADAP Clients

The percentage of clients who received only full-pay medication assistance (where ADAP pays the full cost of medications) decreased from 52.6% in 2015 to 47.5% in 2020. This number is expected to decrease as more ADAP programs begin transitioning clients over to other payor models, such as insurance continuation programs, medication co-pay/deductible assistance, or insurance premium assistance. Each of these models represents cost savings for ADAP programs over the full-pay medication assistance service, as the ADAP programs are no longer paying the full cost of medications.

Breaking these services down by Health and Human Services (HHS) Region (Figure 2):

  • Region 1, which comprises the New England states, had the highest percentage of ADAP clients using medication co-pay/deductible services, with 42.2% of clients using that service.
  • Region 6, which comprises the American South-Central part of the U.S., had the highest percentage of ADAP clients receiving full-pay medication assistance (69.7%), followed by Region 4, which comprises most of the rest of the American South (60.1%)
  • Regions 7 and 8, which comprise the central Midwest and Mountain West, had the highest percentages of ADAP clients utilizing multiple ADAP services (49.6% and 46.3%, respectively).

Figure 2. Map of United States Department of Health and Human Services Regions

United States Department of Health & Human Services Region Map
Photo Source: HRSA, 2022

Potential Concerns for ADAPs

An emergent concern for state ADAP programs has presented itself in the form of the Monkeypox Virus (MPV) outbreak in the United States.

According to a paper published in September 2022, among 1,969 persons diagnosed with MPV in eight U.S. jurisdictions—California, Los Angeles County, San Francisco, the District of Columbia, Georgia, Illinois, Chicago, and New York state—38% were identified in People Living with HIV/AIDS (PLWHA). Additionally, 41% of those diagnosed had been diagnosed with a Sexually Transmitted Infection (STI) in the preceding year. Among persons with MPV, hospitalization was more common in PLWHA than in those without HIV infection (Curran, et al., 2022).

The concern among many HIV advocates is that MPV may become endemic in the MSM community, particularly among those living with HIV. This aligns with additional concerns on the part of infectious disease and public health experts that COVID-19 may end up becoming endemic.

(Editor's Note: The following portion of this post remains unchanged from our coverage of the 2019 ADAP Client-Level Report in June/July 2022 as circumstances have remained the same since that time).

There are some concerns being circulated that ADAP enrollment may begin increasing in the near future. The onset of the COVID-19 global pandemic resulted in the Secretary of HHS declaring quarterly national Public Health Emergencies (PHEs) beginning in January 2020 (Office of the Assistant Secretary for Preparedness and Response, 2022). One of the provisions of the PHE declarations required states to keep people enrolled in state Medicaid programs throughout the PHE in order to receive the temporary increase in the federal share of Medicaid costs. 

When the Secretary fails to renew the PHE, this provision, along with the increased federal funding, will end, meaning that state Medicaid programs will likely begin redetermining eligibility. This could result in an influx of clients moving off of Medicaid and back onto state ADAP programs, which are statutorily required to be the “payor of last resort.”

Additional concerns exist around the reauthorization of the Ryan White HIV/AIDS Program (RWHAP), which has not been reauthorized since 2009. Because the law has no sunset provision, meaning that it can be funded in perpetuity. There have been consistent concerns about reopening RWHAP for reauthorization for fear that Republicans in Congress will gut the program. These concerns have been voiced since at least 2013. As a result, there is little advocacy in favor of reauthorization.

Ultimately, the ADAP program is currently as “safe” as it’s ever been. Waitlists are virtually a thing of the past, meaning that eligible patients are able to gain access to the medications that they need. The ADAP Advocacy Association will continue to monitor the program for both successes and challenges.

To download Table 1 - ADAP enrollment from 2019 to 2020, click here.

References:

  • Curran, K.G., Eberly, K., Russell, O.O., et al. (2022, September 09). HIV and Sexually Transmitted Infections Among Persons with Monkeypox — Eight U.S. Jurisdictions, May 17–July 22, 2022. MMWR Weekly 71(36), 1141-1147. http://dx.doi.org/10.15585/mmwr.mm7136a1
  • Health Resources and Services Administration. (2022, August). Ryan White HIV/AIDS Program AIDS Drug Assistance Program (ADAP) Annual Client-Level Data Report 2020. Rockville, MD: United States Department of Health and Human Services: Health Resources and Services Administration: HIV/AIDS Bureau: Division of Policy and Data https://ryanwhite.hrsa.gov/sites/default/files/ryanwhite/data/hrsa-adap-data-report-2020.pdf
  • Office of the Assistant Secretary for Preparedness and Response. (2022, April 12). Renewal of Determination That A Public Health Emergency Exists. Washington, DC: United States Department of Health and Human Services: Office of the Assistant Secretary for Preparedness and Response: Public Health Emergency Declarations. https://aspr.hhs.gov/legal/PHE/Pages/COVID19-12Apr2022.aspx 

Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates. 

Thursday, October 20, 2022

Rapid HIV Transmission Clusters

By: Ranier Simons, ADAP Blog Guest Contributor

Despite the many medical and scientific advances in the fight against HIV/AIDS, the numbers of new infections and AIDS-related deaths remain markedly high. Globally, in 2021, there were 1.5 million new infections and 650,000 AIDS deaths.[1] Avoidable HIV infections occur among developing and first-world countries, including the United States. The U.S. Centers for Disease Control & Prevention (CDC) reported one such troubling trend in the September 23, 2022, Morbidity and Mortality Weekly Report (MMWR): clusters of rapid HIV transmission among gay, bisexual and other MSM (men who have sex with men).

MSM accounted for 68 percent of new HIV diagnoses in the United States, in 2020. The recent MMWR report examined clusters of rapid HIV transmission identified by the National HIV Surveillance System (NHSS). The NHSS is the primary source for monitoring HIV in the United States. The surveillance system gathers, analyzes, and reports a plethora of information regarding new and existing HIV infections. The CDC provides funding and partners with local and state health departments to collect the data.[2] Part of this data includes HIV-1 nucleotide sequences taken from the bloodwork of infected individuals. Utilizing this database, researchers identified large molecular clusters of rapid transmission. In other words, they could identify clusters of people who shared the same ‘flavor’ of the HIV virus.

TABLE 1. Characteristics of persons in large HIV clusters primarily among gay, bisexual, and other men who have sex with men (N = 29) — United States, 2021*
Photo Source: CDC, MMWR

But as the ADAP Advocacy Association noted several years ago, NHSS also is associated with numerous patient concerns, namely privacy infringement and fueling stigma. Whereas some public health advocates may argue such surveillance is necessary in the fight against HIV/AIDS, others remain skeptical whether the benefits outweigh the risks. For the purpose of this particular blog, that debate will be set aside.

Identifying clusters enables public health professionals to identify demographic and geographic areas of HIV transmission. One hundred and thirty-six rapid transmission clusters were identified during 2018-2019 and followed through to December 2021. Rapid transmission was defined as a cluster with five or more diagnoses in the most recent 12 months.[3] A large cluster was defined as one that grew to contain more than 25 people as of December 2021. Thirty-eight large clusters were detected in 2018-2019. MSM comprised the majority of 29 of those 38 clusters. Also, most clusters of rapid HIV transmission were among MSM. The median growth rate was nine people added to a cluster per year.[3] The MSM majority clusters existed in many different regions of the country, most involving multiple states.

There were 2,901 people in the 136 molecular clusters with rapid transmission. The 38 large clusters contained 1,533 (53%) of the 2,901. The 29 clusters of those 38, which were primarily MSM, contained 985 people. Six clusters were primarily people who injected drugs, and three had no defined transmission category.

HIV Test
Photo Source: POZ

Concerning racial or ethnic groups, as of December 2021, African-Americans were the largest group in 13 of the large MSM clusters, Caucasians were the largest group in nine of the clusters, and Hispanic people were the largest in seven of them.[3] Geographically, the most common region in 14 of the 29 MSM clusters was the South, and 23 clusters included people from multiple regions.[3] As a whole, 70 % lived in large centralized metropolitan areas or large fringe metropolitan areas, and 20% lived in medium metropolitan regions.[3]

Clusters indicate areas where intervention efforts are not successful. Continuing cluster analysis will demonstrate how treatment, prevention, and testing efforts must be modified to be more effective in the affected communities. The rate of transmission in the large MSM clusters was six times the overall U.S. population average for transmission.[3] Approximately 80% of new HIV transmissions are from people unaware of their status or not receiving regular care.[4] The September report is a wake-up call to the desperate need for an effective concerted, multi-pronged social, political, and financial revolution if we are to reach the goal of eradicating HIV.

[1] UNAIDS. (2022) Millions of lives at risk as progress against AIDS falters. Retrieved from https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2022/july/20220727_global-aids-update
[2] Centers for Disease Control and Prevention. (2021, August 9). HIV Statistics Center. Retrived from https://www.cdc.gov/hiv/statistics/index.html
[3] 
Perez, S. PhD et. al (2022). Clusters of Rapid HIV Transmission Among Gay, Bisexual, and Other Men Who Have Sex with Men — United States, 2018–2021. Morbidity and Mortality Weekly Report, 71(38), 1201-1206, https://doi.org/10.15585/mmwr.mm7138a1
[4] 
Li, Zihao PhD et. al. (2019). Vital Signs: HIV Transmission Along the Continuum of Care — United States, 2016. Morbidity and Mortality Weekly Report, 68(11), 267-272, https://doi.org/10.15585/mmwr.mm6811e1

Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates. 

Thursday, October 13, 2022

Fireside Chat Retreat in Chicago, IL Tackles Pressing Public Health Issues

By: Brandon M. Macsata, CEO, ADAP Advocacy Association

The ADAP Advocacy Association hosted its "Fireside Chat" retreat in Chicago, Illinois among key stakeholder groups to discuss pertinent public health issues facing patients in the United States. The Fireside Chat took place on Thursday, September 29th, and Friday, September 30th. Counterfeit Drugs, 340B Drug Pricing Program, and Covid-19 were evaluated and discussed by the 22 diverse stakeholders.

FDR Fireside Chat
Photo Source: Getty Images

The Fireside Chat included moderated white-board style discussion sessions on the following issues:

  • Counterfeit Medicines: What Can We Do to Protect the US Drug Supply Chain from Nefarious Activities — moderated by Shabbir Imber Safdar, Executive Director, Partnership for Safe Medicines (PSM)
  • 340B Drug Discount Program: The Issues Spurring Discussion, Stakeholder Stances, and Possible Resolutions — moderated by Brandon M. Macsata, CEO, ADAP Advocacy Association
  • Covid-19: What is its Impact on HIV, Viral Hepatitis, Sexually Transmitted Infections (STIs), and Substance Use Disorder — moderated by Jen Laws, President & CEO, Community Access National Network (CANN) & Board Member, ADAP Advocacy Association

The discussion sessions were designed to capture key observations, suggestions, and thoughts about how best to address the challenges being discussed at the Fireside Chat. The following represents the attendees:

  • Tez Anderson, Executive Director, Let’s Kick ASS – AIDS Survivor Syndrome
  • Jeff Berry, Executive Director, The Reunion Project
  • Tori Cooper, Director of Community Engagement, Human Rights Campaign
  • Jeffrey S. Crowley, Distinguished Scholar & Program Director at the Infectious Disease Initiatives, O'Neill Institute for National and Global Health Law, Georgetown Law
  • Erin Darling, Associate Vice-President and Counsel, Federal Policy, Merck
  • Heather Eagleton, Director, Government Relations (Midwest), ViiV Healthcare
  • Karen King, fierce Patient Advocate
  • Lisa Johnson-Lett, Peer Support Specialist, AIDS Alabama
  • Jen Laws, President & CEO, Community Access National Network
  • Darnell Lewis, Patient Advocate
  • Brandon M. Macsata, CEO, ADAP Advocacy Association
  • Mike Maginn, HIV Prevention Director, Illinois Public Health Association
  • Aisha McKenzie, Consultant – Event Producer and Administrative Project Management
  • Judith Montenegro, Program Director, Latino Commission on AIDS
  • Murray Penner, Executive Director, North America, Prevention Access Campaign
  • Glen Pietrandoni, Chief Advocacy Officer, Avita Pharmacy
  • Kalvin Pugh, Sr. Manager, Community Engagement at International Association of Providers of AIDS Care
  • Shabbir Imber Safdar, Executive Director, Partnership for Safe Medicines (PSM)
  • Larry Scott-Walker, Executive Director, THRIVE Support Services
  • Sara Stevens, Head, U.S. Issue Advocacy, Novartis
  • Scott Suckow, Senior Consultant, Perry Communications Group
  • Varela, Milani, Patient Advocate, Getting to Zero-Illinois Community Advisory Board

The Covid-19 pandemic is still ongoing. Covid-19 has killed at least 1,051,277 people and infected about 95.4 million in the United States since January 2020, according to data by Johns Hopkins University (CNN, 2022).

With that in mind, the ADAP Advocacy Association implemented strong Covid-19 safety protocols for the Fireside Chat, which included proof of vaccination/booster, robust self-administered testing (prior to travel, upon arrival, and after returning home), complimentary rapid self-test kits and hand sanitizer for each of the attendees, as well as guidelines for masks on commercial travel to the event, and optional masks during the sessions (which some attendees exercised without feeling shunned). 

September 29th marked the one year anniversary of Bill Arnold's passing, so Brandon M. Macsata took a few moments to reflect on his life and his dedication to improving access to care and treatment for all patients, regardless of their ability to pay. 

Bill Arnold standing at Cape Agulhas, South Africa
Bill Arnold standing at Cape Agulhas, South Africa

The ADAP Advocacy Association is pleased to share the following brief recap of the Fireside Chat.

Counterfeit Medicines:

Shabbir Imber Safdar provided a basic overview on the drug supply chain and the ongoing threat poised by counterfeit medicines seeping into it, which is what he often says keeps him up at night. Safdar offered a primer on the Track-and-Trace system, which determines a drug’s current and past locations, and an explanation on how it protects the drug supply chain. To that end, attendees were shared two bottles of medicines; one reflected how a legitimate prescription bottle would look, compared to a counterfeit bottle. The Track-and-Trace systems leverages both technology and regulation to maintain a safe drug supply chain in the United States.

As part of the discussion, Safdar shared some major drug safety incidents in the United States over the last twenty years. They included fake blood thinners recently found in Mexico, counterfeit and diverted HIV medications distributed to pharmacies, counterfeit COVID-19 tests, masks, and unapproved treatments, diverted and unsafe PrEP medications fraudulently obtained and sold to pharmacies and dispensed to patients, counterfeit oncology medicines, and counterfeit IUDs.

There was a deep dive into the recent news on how Gilead Sciences discovered $250 million of counterfeit Biktarvy and Descovy. On August 5, 2021, Gilead Sciences released a press release stating that it had become aware of counterfeit and tampered versions of Biktarvy and Descovy in the supply chain in the United States. The press release resulted from a sealed lawsuit Gilead filed against the sources of the counterfeit in July of 2021. The U.S. District Court of the Eastern District of New York unsealed the documents on January 18, 2022, revealing the details. Stakeholders discussed the reasons why patients are forced to look for alternative sources for their medications.

Additionally, significant discussion centered around the false belief that drug importation would solve ongoing issues over the amount of money Americans pay for their prescription drugs. All cost-estimates yield basically zero savings to federal publicly-financed programs, as well as little help for patients. In reality, consumers in the United States are the largest importers of counterfeit drugs via fake online pharmacies, as well as traveling over the border into Mexico (where the drug supply chain is extremely prone to nefarious activity. With respect to ordering medications online from overseas, some of that could be changing once the United States Postal Service finally implements its small package electronic notification system, which was part of the "STOP Act of 2017" (The Strengthen Opioid Misuse Prevention).

Track-and-Trace on package
Photo Source: pharmaspective.com

 The following materials were shared with retreat attendees:

The ADAP Advocacy Association would like to publicly acknowledge and thank Shabbir Imber Safdar for facilitating this important discussion.

340B Drug Discount Program:

There are probably fewer issues that generate such passion than the need to reform the 340B Drug Discount Program. Macsata (me) offered his perspective on clarifying the purpose and intent of the 340B program, including why reforming the program is in the best interest of the patient community. The program was a well-intended attempt to increase access to prescription drugs for low-income, uninsured patients, and in many ways it has succeeded in doing so. There is no doubt that the program has plugged the funding gaps for many Covered Entities – including Ryan White grantees, and Federally Qualified Health Centers – and that, by in large, federal grantees are not abusing the program to the extent done by hospitals. 

Insufficient funding increases approved by Congress coupled with the lack of buy-in from state legislatures for additional dollars has led many federal grantees to overly rely on their 340B revenue. No matter the program's success, it is no excuse to turn a blind eye to the waste, fraud and abuse that actually serves to hamper even greater patient access, nor is it fruitful to grant a pass to federal and state legislators for failing to appropriate adequate funding for public safety-net programs.

In 2021, annual 340B-related purchases by Covered Entities totaled $43.9 billion, up from only $12.2 billion only six short years ago. Whereas hospitals accounted for most of the growth,[1] federal grantees also benefited from the lucrative revenue stream. In theory, that is good news because it would mean more patients are gaining access to prescription drugs. But in practice, providers are not required by law to apply the discounted savings to patients and there are numerous reports where "charity care" offered to patients has declined over the same six year period. Ryan White grantees, however, aren't absent from program abuse, with several attendees identifying excessive executive compensation as an example. One participant rightly and repeatedly reminded the group, “there are no requirements as to how those dollars are spent.”

In fact, a recent study concluded: "Seventy-two percent of private, nonprofit hospitals had a fair share deficit, meaning they spend less on charity care and community investment than they received in tax breaks."[2] The abuses by hospitals has resulted in a growing number of pharmaceutical manufacturers to place restrictions on their 340B discounts, which isn't necessarily a good thing especially if those restrictions are inadvertently hurting federal grantees. The ADAP Advocacy Association and the Community Access National Network (CANN), back in October 2020, issued a Dear Colleague letter to our industry partners in the pharmaceutical manufacturing space surrounding HIV therapies. The letter sought a carve-out for Ryan White grantees. 

During the discussion, stakeholders kept coming back to a question one attendee asked, "Where does the patient in all of this mess?" Clearly the hospitals benefit from the program, as do federal grantees, as well as contract pharmacies and pharmacy benefit managers (PBMs). In each case, dollars can be tied directly to the program's participants measured by the revenue being reported...except for the patients. It begged the question: Is the program benefitting providers, or patients? That question became more evident because three recent studies found that consumers in the United States are burdened by $195 billion in medical debt. Yes, billion!

Generally, there was agreement that the 340B Drug Discount Program is long-overdue for an update. Diving into the specifics over what needs to be reform saw a bit more variation of opinion. 

340B Drug Pricing Program
Photo Source: CANN YouTube Channel

The following materials were shared with retreat attendees:

Editor's Note: The ADAP Advocacy Association has offered opinions on 340B over the last several years, including Industry’s Changes to 340B Drug Discount Program (April 2022), 340B – Reply Hazy, Try Again (January 2020), The Federal 340B Program: A Call to Order (March 2019), and 340B Program: Don't Throw the Baby Out with the Bathwater (March 2017)

Covid-19's Impact on Public Health:

Covid-19’s impact on public health programs remains constant, evidenced by a slew of recent news reports documenting area after area falling behind with respect to efforts on prevention, testing, and treatment. Jen Laws took the liberty of deviating the discussion away from policy issues in favor of assessing patient advocacy and provider services as a response. With concentration on sustainability and succession planning, participants reflected how the crisis phase of the pandemic highlighted not just the weaknesses in public health programs, but also re-emphasized the need for HIV advocacy to consider appropriate succession planning and mentorship, as much as our service organization partners need to find room in their budgets to hire enough staff to not burn out their existing staff. 

Reminding the audience, Laws reflected, “Because eventually Bill Arnold dies.” The statement hit home for the room’s audience, referring to the empty seat draped in the fishing vest with the AIDS red ribbon on the lapel once worn by our Lion of HIV/AIDS advocacy. The group agreed that agencies need to plan better, and they have to be willing to make these investments now, not later. 

The discussion also focused on how the Covid-19 challenges have been further complicated by the emergence of yet another public health crisis: Monkeypox. The public health infrastructure is literally at a breaking point, which isn't helped by ongoing public attacks by certain politicians seeking nothing more than soundbites. 

Sign that reads: Get Tested for COVID Today"
Photo Source: MedPage Today

The following materials were shared with retreat attendees: 

The ADAP Advocacy Association would like to publicly acknowledge and thank Jen Laws for facilitating this important discussion.

Additional Fireside Chats are planned for 2023.

[1] Pitts, Peter J. and Robert Popovian (Fall 2022). 340B and the Warped Rhetoric of Healthcare Compassion. Food and Drug Law Institute. Retrieved online at https://www.fdli.org/2022/09/340b-and-the-warped-rhetoric-of-healthcare-compassion/

Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates.